The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-18-406.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,389,878 in first-year total cost, median $657,073.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-G (M1)]6
- Special Emphasis Panel[ZHL1 CSR-G (O2)]3
- Special Emphasis Panel[ZHL1 CSR-G (F1)]2
Most frequent institutions
- EMORY UNIVERSITY1
- NORTHWESTERN UNIVERSITY AT CHICAGO1
- OREGON HEALTH & SCIENCE UNIVERSITY1
- PENNSYLVANIA STATE UNIV HERSHEY MED CTR1
- STANFORD UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | PCSK9 Inhibition after Heart Transplantation1R61HL139929-01A1 | FEARON, WILLIAM F | STANFORD UNIVERSITY, CA | $435,534 | ZHL1 |
| 2018 | A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)1R61HL139852-01 | CIOLINO, JODY D.HUFFMAN, MARK D | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $1,228,452 | ZHL1 |
| 2018 | Advanced REperfusion STrategies- The ARREST Trial1R61HL142696-01 | AUFDERHEIDE, TOM PAULYANNOPOULOS, DEMETRIS | UNIVERSITY OF MINNESOTA, MN | $750,258 | ZHL1 |
| 2018 | Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)1R61HL141047-01 | HOFFMANN, UDOHSUE, PRISCILLA Y.TAWAKOL, AHMED A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $729,903 | ZHL1 |
| 2018 | REHAB-PH Trial: Repurposing a Histamine Antagonist to Benefit Patients with Pulmonary Hypertension1R61HL142539-01 | LEARY, PETER J | UNIVERSITY OF WASHINGTON, WA | $685,472 | ZHL1 |
| 2018 | Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study1R61HL138650-01A1 | AZIZ, MICHAELTREGGIARI, MIRIAM | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $657,073 | ZHL1 |
| 2018 | Comparative effectiveness of social physical play and traditional exercise programming1R61HL142679-01 | SCIAMANNA, CHRISTOPHER N. | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $643,916 | ZHL1 |
| 2018 | The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure1R61HL139943-01 | ABBATE, ANTONIOVAN TASSELL, BENJAMIN W | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $532,674 | ZHL1 |
| 2018 | Targeting of UnControlled Hypertension in Emergency Department (TOUCHED)1R61HL139454-01A1 | PRENDERGAST, HEATHER MARIE | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $505,284 | ZHL1 |
| 2018 | Behavioral Economic Approaches to Increase Physical Activity among Patients with Elevated Risk for Cardiovascular Disease1R61HL141440-01 | PATEL, MITESH S.VOLPP, KEVIN G | UNIVERSITY OF PENNSYLVANIA, PA | $446,212 | ZHL1 |
| 2017 | Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial Disease1R61HL138657-01 | QUYYUMI, ARSHED A | EMORY UNIVERSITY, GA | $775,100 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.